Literature DB >> 22868819

Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis.

Kerry McBrien, Doreen M Rabi, Norm Campbell, Lianne Barnieh, Fiona Clement, Brenda R Hemmelgarn, Marcello Tonelli, Lawrence A Leiter, Scott W Klarenbach, Braden J Manns.   

Abstract

BACKGROUND Treatment of hypertension in patients with diabetes mellitus (DM) has been shown to improve cardiovascular outcomes; however, the value of intensive blood pressure (BP) targets remains uncertain. We sought to determine the effectiveness and safety of treating BP to intensive targets (upper limit of 130 mm Hg systolic and 80 mm Hg diastolic) compared with standard targets (upper limit of 140-160 mm Hg systolic and 85-100 mm Hg diastolic) in patients with type 2 DM. METHODS Using electronic databases, bibliographies, and clinical trial registries, we conducted a systematic review and meta-analysis to identify randomized trials enrolling adults diagnosed as having type 2 DM and comparing prespecified BP targets. Data on study characteristics, risk for bias, and outcomes were collected. Random-effects models were used to pool relative risks and risk differences for mortality, myocardial infarction, and stroke. RESULTS The use of intensive BP targets was not associated with a significant decrease in the risk for mortality (relative risk difference, 0.76; 95% CI, 0.55-1.05) or myocardial infarction (relative risk difference, 0.93; 95% CI, 0.80-1.08) but was associated with a decrease in the risk for stroke (relative risk, 0.65; 95% CI, 0.48-0.86). The pooled analysis of risk differences associated with the use of intensive BP targets demonstrated a small absolute decrease in the risk for stroke (absolute risk difference, -0.01; 95% CI, -0.02 to -0.00) but no statistically significant difference in the risk for mortality or myocardial infarction. CONCLUSION Although the use of intensive compared with standard BP targets in patients with type 2 DM is associated with a small reduction in the risk for stroke, evidence does not show that intensive targets reduce the risk for mortality or myocardial infarction.

Entities:  

Year:  2012        PMID: 22868819     DOI: 10.1001/archinternmed.2012.3147

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  37 in total

1.  The results of a survey of physicians about the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 and its clinical use.

Authors:  Masaki Mogi; Naoyuki Hasebe; Masatsugu Horiuchi; Kazuaki Shimamoto; Satoshi Umemura
Journal:  Hypertens Res       Date:  2016-05-12       Impact factor: 3.872

Review 2.  Type 2 diabetes and cardiovascular disease: what next?

Authors:  Joshua J Joseph; Sherita Hill Golden
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

3.  Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials.

Authors:  G Jerums; S Panagiotopoulos; E Ekinci; R J MacIsaac
Journal:  J Hum Hypertens       Date:  2015-01-22       Impact factor: 3.012

4.  Diabetes: no clear advantage for intensive blood pressure control in T2DM.

Authors:  Caroline Barranco
Journal:  Nat Rev Endocrinol       Date:  2012-08-28       Impact factor: 43.330

5.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 6.  Update on blood pressure control and renal outcomes in diabetes mellitus.

Authors:  Mark Henry Joven; Robert J Anderson
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

7.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 8.  Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review.

Authors:  Gerardo Moreno; Carol M Mangione
Journal:  J Am Geriatr Soc       Date:  2013-11       Impact factor: 5.562

9.  Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.

Authors:  Joshua D Bundy; Changwei Li; Patrick Stuchlik; Xiaoqing Bu; Tanika N Kelly; Katherine T Mills; Hua He; Jing Chen; Paul K Whelton; Jiang He
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 10.  Diabetes: treating hypertension.

Authors:  Sandeep Vijan
Journal:  BMJ Clin Evid       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.